About TetraLogic Pharmaceuticals Corporation (OTCMKTS:TLOG)
TetraLogic Pharmaceuticals Corporation is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing small molecule therapeutics in oncology, infectious diseases and autoimmune diseases. The Company's segment is the identification and development of novel small molecule therapies in oncology and infectious diseases. The Company has approximately two clinical-stage product candidates in development, such as birinapant and SHAPE. SHAPE is the Company's histone deacetylase (HDAC) inhibitor that it is developing for topical use for the treatment of early-stage cutaneous T-cell lymphoma (CTCL). The Company is also exploring studying SHAPE in alopecia areata, an autoimmune skin disease. SHAPE has been granted the United States orphan drug designation for CTCL. Birinapant is a small molecule therapeutic that mimics Second Mitochondrial Activator of Caspases (SMAC)-mimetic, which leads to apoptosis or cell-death in damaged cells.
Industry, Sector and Symbol:
- Industry: Biotechnology
- Sub-Industry: N/A
- Sector: Medical
- Symbol: OTCMKTS:TLOG
- Previous Symbol: NASDAQ:TLOG
- CUSIP: N/A
- Web: www.tetralogicpharma.com
Sales & Book Value:
- Annual Sales: N/A
- Price / Sales: N/A
- Book Value: ($0.24) per share
- Price / Book: -0.18
- Outstanding Shares: 24,470,000
Frequently Asked Questions for TetraLogic Pharmaceuticals Corporation (OTCMKTS:TLOG)
What is TetraLogic Pharmaceuticals Corporation's stock symbol?
TetraLogic Pharmaceuticals Corporation trades on the OTCMKTS under the ticker symbol "TLOG."
How were TetraLogic Pharmaceuticals Corporation's earnings last quarter?
TetraLogic Pharmaceuticals Corporation (OTCMKTS:TLOG) issued its quarterly earnings results on Thursday, February, 26th. The biopharmaceutical company reported ($0.53) EPS for the quarter, missing the Zacks' consensus estimate of ($0.39) by $0.14. View TetraLogic Pharmaceuticals Corporation's Earnings History.
When will TetraLogic Pharmaceuticals Corporation make its next earnings announcement?
Who are some of TetraLogic Pharmaceuticals Corporation's key competitors?
Some companies that are related to TetraLogic Pharmaceuticals Corporation include Function(x) (FNCX), Cardinal Energy Group (CEGX), Sabine Oil & Gas Corp (SOGCQ), Towerstream Corporation (TWER), Republic Airways Holdings (RJETQ), KiOR (KIORQ), Omnitek Engineering Corp. (OMTK), Affymax (AFFY), Horsehead Holding Corp. (ZINCQ), Inventergy Global (INVT), Viewtran Group (VIEWF), Excel Maritime Carriers LLC (EXMCQ), Alpha Natural Resources (ANRZQ), TerraVia Holdings (TVIAQ), Blue Ridge Mountain Resources (MHRCQ), GSE Holding (GSEH), Education Management Corp. (EDMC) and Atlas Resource Partners, L.P. (ARPJQ).
Who are TetraLogic Pharmaceuticals Corporation's key executives?
TetraLogic Pharmaceuticals Corporation's management team includes the folowing people:
- Andrew L. Pecora M.D., Independent Chairman of the Board
How do I buy TetraLogic Pharmaceuticals Corporation stock?
Shares of TetraLogic Pharmaceuticals Corporation can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is TetraLogic Pharmaceuticals Corporation's stock price today?
One share of TetraLogic Pharmaceuticals Corporation stock can currently be purchased for approximately $0.04.
How big of a company is TetraLogic Pharmaceuticals Corporation?
TetraLogic Pharmaceuticals Corporation has a market capitalization of $1.06 million. The biopharmaceutical company earns ($49,720,000.00) in net income (profit) each year or ($1.65) on an earnings per share basis.
How can I contact TetraLogic Pharmaceuticals Corporation?
TetraLogic Pharmaceuticals Corporation's mailing address is 343 PHOENIXVILLE PIKE, MALVERN PA, 19355. The biopharmaceutical company can be reached via phone at 610-889-9900 or via email at [email protected]
MarketBeat Community Rating for TetraLogic Pharmaceuticals Corporation (OTCMKTS TLOG)MarketBeat's community ratings are surveys of what our community members think about TetraLogic Pharmaceuticals Corporation and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Analysts' Consensus Rating for TetraLogic Pharmaceuticals Corporation (OTCMKTS:TLOG) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||0 Sell Ratings, 0 Hold Ratings, 0 Buy Ratings, 0 Strong Buy RatingsNo ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Analysts' Consensus Price Target: ||N/A|
Consensus Price Target History for TetraLogic Pharmaceuticals Corporation (OTCMKTS:TLOG)
Analysts' Ratings History for TetraLogic Pharmaceuticals Corporation (OTCMKTS:TLOG)
(Data available from 11/17/2015 forward)
|1/7/2016||Roth Capital||Lower Price Target||Buy||$5.00 -> $1.00|
Earnings History and Estimates Chart for TetraLogic Pharmaceuticals Corporation (OTCMKTS:TLOG)
Earnings History by Quarter for TetraLogic Pharmaceuticals Corporation (OTCMKTS TLOG)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|11/23/2017|| || || || || || || || |
Earnings Estimates for TetraLogic Pharmaceuticals Corporation (OTCMKTS:TLOG)
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for TetraLogic Pharmaceuticals Corporation (OTCMKTS:TLOG)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for TetraLogic Pharmaceuticals Corporation (OTCMKTS TLOG)
Insider Ownership Percentage: 15.40%
Institutional Ownership Percentage: 0.03%
Insider Trades by Quarter for TetraLogic Pharmaceuticals Corporation (OTCMKTS TLOG)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|2/9/2016||Lifesciences Ii L.P. Clarus||Major Shareholder||Sell||333,630||$0.17||$56,717.10|| |
|2/5/2016||Lifesciences Ii L.P. Clarus||Major Shareholder||Sell||1,415,490||$0.18||$254,788.20|| |
|2/2/2016||Lifesciences Ii L.P. Clarus||Major Shareholder||Sell||369,132||$0.19||$70,135.08|| |
|1/28/2016||Lifesciences Ii L.P. Clarus||Major Shareholder||Sell||311,930||$0.28||$87,340.40|| |
|7/10/2015||Andrew L Pecora||Director||Buy||50,000||$2.68||$134,000.00|| |
|7/9/2015||Andrew L Pecora||Director||Buy||50,000||$2.40||$120,000.00|| |
|7/2/2015||Paul J Schmitt||Director||Buy||10,000||$2.34||$23,400.00|| |
|3/27/2015||Pete A Meyers||CFO||Buy||5,000||$4.35||$21,750.00|| |
|3/26/2015||J Kevin Buchi||CEO||Buy||5,000||$4.23||$21,150.00|| |
|1/7/2015||J Kevin Buchi||CEO||Buy||5,000||$5.04||$25,200.00|| |
|12/10/2014||Colin Glenn Begley||SVP||Buy||5,900||$6.16||$36,344.00|| |
|12/9/2014||J Kevin Buchi||CEO||Buy||5,000||$6.01||$30,050.00|| |
|12/4/2014||Pete A Meyers||CFO||Buy||1,034||$4.94||$5,107.96|| |
|12/2/2014||J Kevin Buchi||CEO||Buy||10,000||$4.99||$49,900.00|| |
|11/26/2014||Colin Glenn Begley||SVP||Buy||3,100||$4.86||$15,066.00|| |
|11/26/2014||Lesley Russell||COO||Buy||20,000||$4.90||$98,000.00|| |
|11/25/2014||Colin Glenn Begley||SVP||Buy||2,000||$4.85||$9,700.00|| |
|11/18/2014||J Kevin Buchi||CEO||Buy||10,000||$4.82||$48,200.00|| |
|11/17/2014||Andrew L Pecora||Director||Buy||20,000||$4.53||$90,600.00|| |
|11/12/2014||Peter A Meyers||CFO||Buy||5,000||$3.98||$19,900.00|| |
|11/11/2014||J Kevin Buchi||CEO||Buy||10,000||$3.93||$39,300.00|| |
|11/10/2014||Paul J Schmitt||Director||Buy||20,000||$4.10||$82,000.00|| |
|12/17/2013||J Kevin Buchi||CEO||Buy||285,714||$7.00||$1,999,998.00|| |
|12/17/2013||James N Woody||Director||Buy||261,427||$7.00||$1,829,989.00|| |
|12/17/2013||Peter A Meyers||CFO||Buy||142,857||$7.00||$999,999.00|| |
|12/17/2013||Ventures Vii Lp Healthcare||Major Shareholder||Buy||713,463||$7.00||$4,994,241.00|| |
Headline Trends for TetraLogic Pharmaceuticals Corporation (OTCMKTS:TLOG)
Latest Headlines for TetraLogic Pharmaceuticals Corporation (OTCMKTS TLOG)
TetraLogic Pharmaceuticals Corporation (OTCMKTS TLOG) Chart for Friday, November, 17, 2017